Evotec's Crucial April Report: A Test of Restructuring Credibility

Evotec faces investor pressure to deliver a credible 2026 financial roadmap on April 8, following aggressive cost cuts, a major asset sale, and a 14% stock decline.

All eyes are on Evotec as it prepares to release its annual report on April 8, 2026. The market is demanding one key deliverable: a credible and resilient financial forecast for the year ahead. This follows a series of aggressive corporate actions, including deeper-than-expected cost cuts and a major asset sale, which have yet to fully reassure investors.

Recent share price performance underscores the prevailing market skepticism. Over a 30-day period, the stock has declined by 14.07%, with its current price of €5.46 sitting notably below the 50-day moving average of €6.07.

Accelerated Restructuring Under "Priority Reset"

New details from a corporate presentation on March 5, 2026, reveal that Evotec's "Priority Reset" restructuring initiative is progressing more aggressively than initially outlined. The company has already surpassed its original target for cost reductions, which was set at €60 million.

This drive for efficiency has come with a significant human and strategic cost. Between March 2024 and June 2025, the headcount in the Discovery & Preclinical Development segment was reduced by approximately 600 full-time positions. This move is central to the firm's strategic pivot toward a less capital-intensive operational model.

Management has identified several levers for medium-term value creation, including improved operational efficiency and enhanced monetization of its Just?Evotec?Biologics technology platform. Furthermore, the company anticipates additional milestone and licensing revenues from its pipeline, which the presentation notes contains over 100 assets, with about 60% of these in collaborative partnerships.

Toulouse Sale Bolsters Financial Position

A cornerstone of the corporate transformation is the completed sale of the JEB biologics site in Toulouse to Sandoz. The transaction includes a perpetual license for continuous biologics manufacturing.

Financially, the deal is substantial, providing an immediate cash infusion of approximately $350 million. It also promises over $300 million in potential future revenue from additional licensing, development fees, and success-based milestones in the coming years. Strategically, this divestiture aligns with the goal of scaling through technology monetization while reducing capital intensity.

The Pressure for a Convincing 2026 Roadmap

The importance of the upcoming guidance is highlighted by the company's recent nine-month figures for 2025. Group revenue for the period reached €535.1 million, representing a 7.1% decrease year-over-year. The Discovery & Preclinical Development segment faced particular pressure, with revenue falling 12.3% to €392.1 million.

Despite these headwinds, Evotec continues to affirm its medium-term targets. These include achieving an 8–12% compound annual growth rate (CAGR) in revenue for the 2024–2028 period and delivering an adjusted EBITDA margin exceeding 20% by 2028. The central question is whether the April 8 report can provide a believable roadmap that convincingly links current cost-saving measures with these long-term profitability goals.

Investor attention is also focused on shifts in the shareholder register. As of January 13, 2026, Goldman Sachs reported a voting rights stake of 6.12% (up from 3.68%) held via shares and financial instruments. Additionally, Triton GP HoldCo SARL and Mubadala Investment Company each maintain positions exceeding 5%.

Ultimately, the narrative converges on a single date. The annual report and 2026 forecast due on April 8, 2026, must demonstrate whether the "Priority Reset" is a genuine strategic repositioning rather than a simple austerity exercise. More critically, it needs to substantiate the path toward the promised >20% EBITDA margin by 2028 with concrete, credible milestones.